Citigroup Inc Gracell Biotechnologies Inc. Transaction History

Citigroup Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$2.43 - $10.04 $1,142 - $4,718	470 Added 55.56%	1,316 $13,000
Q3 2023 Nov 09, 2023	SELL	$2.83 - $4.9 $1,066 - $1,847	-377 Reduced 30.83%	846 $2,000
Q2 2023 Aug 10, 2023	BUY	$1.45 - $6.07 $671 - $2,810	463 Added 60.92%	1,223 $4,000
Q1 2023 May 11, 2023	SELL	$1.8 - $2.5 $19 - $27	-11 Reduced 1.43%	760 $1,000
Q4 2022 Feb 09, 2023	BUY	$2.08 - $3.96 $110 - $209	53 Added 7.38%	771 $1,000
Q3 2022 Nov 10, 2022	SELL	$2.08 - $5.15 $4,931 - $12,210	-2,371 Reduced 76.76%	718 $2,000
Q2 2022 Aug 10, 2022	SELL	$1.95 - $5.5 $713 - $2,013	-366 Reduced 10.59%	3,089 $17,000
Q1 2022 May 12, 2022	SELL	$1.83 - $5.52 $5,524 - $16,664	-3,019 Reduced 46.63%	3,455 $8,000
Q4 2021 Feb 10, 2022	BUY	$5.65 - $14.9 $31,052 - $81,890	5,496 Added 561.96%	6,474 $39,000
Q3 2021 Nov 10, 2021	BUY	$9.91 - $14.84 $9,691 - $14,513	978 New	978 $14,000

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.